Moleculin Biotech Stock Soars 13.44% on Clinical Trial Expansion

On July 9, 2025, Moleculin Biotech's stock surged by 13.44% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Moleculin Biotech has expanded its Phase 3 MIRACLE clinical trial into the country of Georgia, a move that is expected to enhance the trial's reach and potentially accelerate the enrollment process. The company plans to add 16 additional clinical sites in Europe and the US by the end of August, with the goal of having more than 30 sites by the end of the year for Part A of the trial. This expansion is part of Moleculin's broader strategy to conduct global clinical trials, as evidenced by the European Medicines Agency's approval for Annamycin in nine EU countries. The company's proactive approach to expanding its clinical trial footprint is likely to have a positive impact on its stock performance, as it demonstrates Moleculin's commitment to advancing its drug development pipeline and bringing innovative treatments to patients.